Authors

Latest:

Sentinel Lymph Node Excision Has Value in Endometrial Cancer

Although the therapeutic utility of lymphadenectomy is uncertain, it continues to provide information for staging and helps to guide postoperative adjuvant treatment for patients with endometrial cancer.

Sumit K. Subudhi, MD, PhD

Latest:

Ongoing Clinical Trials in the Metastatic CRPC Setting

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Sundar Jagannath, MD

Latest:

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma

Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.

Sundar Jagannath, MD, Tisch Cancer Institute

Sung W. Choi, MD

Latest:

Dr. Sung Choi on Vorinostat in GVHD Prevention

Sung W. Choi, MD, Assistant Professor, University of Michigan, discusses the results of a phase I/II trial examining the use of the histone deacetylase (HDAC) inhibitor vorinostat in graft-versus-host disease (GVHD) prevention.

Sunil Verma, MD

Latest:

Dr. Verma Discusses Biosimilars for Trastuzumab

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the potential role for trastuzumab (Herceptin) biosimilars.

Sunil Verma, MD, MSEd, FRCPC

Latest:

Dr. Verma Discusses Clinical Trial Endpoints in Metastatic Breast Cancer

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in early-stage breast cancer.

Sunil Verma, MD, MSEd, FRCPC, University of Calgary

Supriya G. Mohile, MD, MS

Latest:

Dr. Mohile On Prostate Cancer in Elderly Patients

Dr. Supriya Mohile from the University of Rochester Medical Center Discusses Prostate Cancer in Elderly Patients

Supriya Gupta Mohile, MD, MS

Latest:

Dr Gupta on Updated Efficacy Data With Liso-Cel in Second-Line Relapsed/Refractory LBCL

Supriya Gupta, MD, discusses updated efficacy data on liso-cel as second-line therapy for large B-cell lymphoma.

Surabhi Dangi-Garimella, PhD

Latest:

Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL

Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.

Surabhi Dangi-Garimella, PhD, from AJMC.com

Latest:

Trial Backs 50-Gene Test in Neoadjuvant Setting

Neoadjuvant chemotherapy for women diagnosed with breast cancer can help shrink a tumor prior to surgery, which can make the procedure minimally invasive and potentially influence prognosis.

Surendra Srinivas Shastri, MD

Latest:

Dr. Shastri on Vinegar as a Cervical Cancer Screening Tool

Surendra Srinivas Shastri, MD, Professor, Preventive Oncology, Tata Memorial Hospital, Mumbai, India, discusses the results of a study looking at vinegar (acetic acid) as a cervical cancer screening tool.

Suresh A. Ramalingam, MD

Latest:

Dr. Ramalingam on the Results of an Exploratory Analysis of the CheckMate 227 Trial in NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the results of an exploratory analysis of the ongoing phase 3 CheckMate 227 trial in advanced non–small cell lung cancer.

Suresh Ramalingam, MD,

Latest:

Dr. Ramalingam on Investigating Osimertinib Combination Approaches in NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses ongoing trials investigating osimertinib combination approaches in non-small cell lung cancer.

Suresh Ramalingam, MD, Winship Cancer Institute Emory University

Latest:

Dr. Ramalingam on the Clinical Examination of Patritumab Deruxtecan in NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the exploration of patritumab deruxtecan in non–small cell lung cancer.

Suresh Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University

Latest:

Dr. Ramalingam on the Potential of HER2 as a Driver Mutation in NSCLC

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

Suresh S. Ramalingam

Latest:

Dr. Ramalingam on the Efficacy of Trastuzumab Deruxtecan in HER2+ NSCLC

Suresh S. Ramalingam, MD, FASCO, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive non–small cell lung cancer.

Suresh S. Ramalingam, MD

Latest:

Unveiling the Plenary and Gynecologic Cancer Abstracts: Drs Ramalingam and O'Malley

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.